Literature DB >> 26177778

Influence of a Nigerian honey on CYP3A4 biotransformation of quinine in healthy volunteers.

S I Igbinoba1, M A Akanmu2, C O Onyeji3, J O Soyinka3, A R Owolabi4, T I Nathaniel5, S V Pullela6, J M Cook6.   

Abstract

WHAT IS KNOWN AND
OBJECTIVES: Some studies, howbeit with conflicting reports, have suggested that consumption of honey has a potential to modulate drug metabolizing enzymes which may result in a honey-drug interaction. Numerous studies have established that honey varies in composition, influenced by the dominant floral, processing and environmental factors. Thus, variation in honey composition may be a contributing factor to the controversial results obtained. No previous drug interaction study has been carried out with any honey from Africa. CYP 3A4 is an important enzyme in drug metabolism studies as it is involved in the metabolism of over 50% of drugs in clinical use and quinine remains very relevant in malaria treatment in the tropics, and we therefore determined whether there is potential drug interaction between a Nigerian honey and quinine, a drug whose metabolism to 3-hydroxyquinine is mediated majorly by CYP3A4.
METHODS: In a three-phase randomized crossover study with a washout period of 2 weeks between each treatment phase, ten (10) healthy volunteers received quinine sulphate tablet (600 mg single dose) alone (phase 1) or after administration of 10 ml of honey (Phase 2) and 20 mL of honey (Phase 3) twice daily for seven (7) days. Blood samples were collected at the 16th hour post-quinine administration in each phase, and quinine and its major metabolite, 3-hydroxyquinine, were analysed using a validated HPLC method.
RESULTS: After scheduled doses of honey, the mean metabolic ratios of quinine (3-hydroxyquinine/quinine) increased by 24·4% (with 10 mL of honey) and reduced by 23·9% (with 20 mL of honey) when compared to baseline. These magnitudes of alteration in the mean metabolic ratios were not significant (P > 0·05; Friedman test). The geometric mean (95% CI) for the metabolic ratio of quinine before and after honey intake at the two dose levels studied was 0·82 (0·54, 1·23) and 1·29 (0·96, 1·72), respectively, and were also not significant (P = 0·296 and 0·081 respectively; Student's t-test). WHAT IS NEW AND
CONCLUSION: This is a pioneer study on the effect of Nigerian/African honey on quinine metabolism. The findings indicated that low and high doses of honey did not significantly affect metabolism of quinine to 3-hydroxyquinine. This suggests that CYP3A4 activity is not significantly altered following low or high dose of honey, as CYP3A4 has been reported to be responsible for the conversion of quinine to 3-hydroxyquinine. In conclusion, the outcome of this study suggests that there may be no potential significant metabolic interaction between Nigerian honey and quinine administration.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  CYP3A4; Nigerian honey; herb-drug interaction; quinine

Year:  2015        PMID: 26177778      PMCID: PMC4871767          DOI: 10.1111/jcpt.12303

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  30 in total

1.  Effect of honey on carbamazepine kinetics in rabbits.

Authors:  K Koumaravelou; C Adithan; C H Shashindran; Mohammed Asad; Benny K Abraham
Journal:  Indian J Exp Biol       Date:  2002-05       Impact factor: 0.818

2.  Influence of honey on the pharmacokinetics of phenytoin in healthy rabbits.

Authors:  S K Garg
Journal:  Methods Find Exp Clin Pharmacol       Date:  2003-06

3.  Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits.

Authors:  K Koumaravelou; C Adithan; C H Shashindran; M Asad; Benny K Abraham
Journal:  Indian J Exp Biol       Date:  2002-10       Impact factor: 0.818

4.  Grapefruit juice has no effect on quinine pharmacokinetics.

Authors:  P C Ho; S C Chalcroft; P F Coville; S Wanwimolruk
Journal:  Eur J Clin Pharmacol       Date:  1999-07       Impact factor: 2.953

5.  Single plasma sampling to predict oral clearance of CYP3A probe midazolam.

Authors:  B Zhu; D S Ou-Yang; Z N Cheng; S L Huang; H H Zhou
Journal:  Acta Pharmacol Sin       Date:  2001-07       Impact factor: 6.150

6.  Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.

Authors:  Pankaj B Desai; Srikanth C Nallani; Rucha S Sane; Linda B Moore; Bryan J Goodwin; Donna J Buckley; Arthur R Buckley
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

7.  Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?

Authors:  Sompon Wanwimolruk; Mary F Paine; Susan N Pusek; Paul B Watkins
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

Review 8.  The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; Scott R Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  J Clin Pharmacol       Date:  2003-05       Impact factor: 3.126

9.  The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

Authors:  Magnus Christensen; Katarina Andersson; Per Dalén; Rajaa A Mirghani; Gary J Muirhead; Anna Nordmark; Gunnel Tybring; Anneli Wahlberg; Umit Yaşar; Leif Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

Review 10.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Authors:  Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-05-24       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.